Both PDE2A and PDE10A inhibitors are being studied in the clinic as potential treatments for schizophrenia (Siuciak et al., 2006), Huntington’s disease (Giampa et al., 2010), Parkinson’s disease (Niccolini et al., 2015), and other movement and neuropsychiatric disorders (Nishi and Snyder, 2010; Menniti et al., 2006). The gene discussed is PDE2A; the disease is Huntington disease.